

Ref: EPL/CS/SE/0057/2026

Date: July13, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai - 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Acquisition

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), we wish to inform you that the Company has today, i.e., July 13, 2026, executed Share Transfer Agreements with all the individual shareholders of Gennova Biopharmaceuticals Limited ("Gennova"), a subsidiary of the Company, for acquisition of 663,865 Equity Shares, constituting 12.05% of the total issued and paid up capital of Gennova. Upon completion of the aforesaid acquisition, Gennova would become a wholly-owned subsidiary of the Company.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the LODR Regulations are provided in **Annexure A**, enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Amruta Yangelwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687

Encl: As above

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sr. No	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	Gennova Biopharmaceuticals Limited, having CIN: U24231PN2001PLC016253 and registered office at Plot No. P-1 & P-2, IT - BT Park, Phase II, M.I.D.C, Hinjawadi, Pune - 411057, Maharashtra, India ("Gennova"). Gennova is a Subsidiary of the Company, involved in the business of research and development, manufacturing and marketing of biotechnology-based products. Turnover for the Financial Year ended March 31, 2026: Rs. 4,917.42 Million PAT for the the Financial Year ended March 31, 2026: Rs. 54.25 Million Authorized Share Capital: Rs. 650,000,000/- (Rupees Six Hundred and Fifty Million only) Paid-up Share Capital: Rs. 55,113,650/- (Rupees Fifty-Five Million One Hundred Thirteen Thousand Six Hundred and Fifty only)
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The Company currently owns 87.95% shareholding in Gennova, a Subsidiary and therefore, a related party. Further, a Promoter and Director of the Company is also a Director and Member of Gennova. The relatives of such Director who are Members of Gennova are also considered related parties. The transaction shall be undertaken at arm's length.
c)	Industry to which the entity being acquired belongs	Pharmaceuticals

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

d)	Objects and impacts of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Proposed acquisition/purchase of 663,865 Equity Shares, constituting 12.05% of the total issued and paid-up capital of Gennova from all its individual shareholders, will make Gennova a wholly-owned subsidiary of the Company. Emcure has entered into Share Purchase Agreement(s) with individual shareholders.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
f)	Indicative time period for completion of the acquisition	On or before July 31, 2026
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash Consideration
h)	Cost of acquisition or the price at which the shares are acquired	An aggregate consideration of Rs. 2,318.7 Million payable in cash in one or more tranches on closing.
i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	The existing Equity shareholding of the Company in Gennova is 87.95%. Post-acquisition, the shareholding of the Company in Gennova will be 100%.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	1. Background: Gennova was incorporated on June 19, 2001, as a public limited company under the Companies Act, 1956, with name 'Emcure Dragon Biotech Limited'. The said name was subsequently changed to Emcure Biotech Limited on October 23, 2001. The name 'Emcure Biotech Limited' was further changed to 'Gennova Biopharmaceuticals Limited' on February 15, 2006. 2. Products / line of business: Gennova is involved in the business of research and development, manufacturing and marketing of biotechnology-based products.

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

		3. Date of incorporation: June 19, 2001 4. Last 3 years' turnover: i) FY 2025-26: Rs. 4,917.42 Million ii) FY 2024-25: Rs. 4,299.46 Million iii) FY 2023-24: Rs. 4,220.82 Million 5. Country of operation: India
--	--	---

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251